A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)

Inclusion Criteria: * In general good health * Female participants have a negative pregnancy test just prior to vaccination on Day 1 Exclusion Criteria: * History of Hepatitis B Infection or vaccination * Known or suspected hypersensitivity to any component of Recombivax HB™ vaccine (e.g., aluminum, yeast) * Administration of hepatitis B immune globulin, serum immune globulin, or any other blood-derived product within 3 months prior to vaccination on Day 1 * Receipt of an inactivated virus vaccine within 14 days or a live virus vaccine within 30 days prior to vaccination on Day 1 * Participation on prior study using an investigational drug or vaccine in prior 3 months * Known or suspected impairment of immunologic function or recent use of immunomodulatory medications, excluding topical or inhaled steroids * Pregnant or nursing women or women planning to become pregnant within the study period